サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468502

好中球減少症治療市場レポート：治療法、流通チャネル、地域別、2024～2032年

Neutropenia Treatment Market Report by Treatment (Colony-Stimulating Factors, Antibiotics, Antifungals, Antivirals), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 137 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
好中球減少症治療市場レポート：治療法、流通チャネル、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の好中球減少症治療市場規模は2023年に153億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて4.9%の成長率（CAGR）を示し、2032年までに238億米ドルに達すると予測しています。クラウドプラットフォームの採用の増加、スマートフォンの販売台数の増加、広範な研究開発（R&D）活動が市場を牽引する主要要因となっています。

好中球減少症は、身体が感染症と闘うのを助ける白血球（WBC）の数が異常に少なくなることを特徴とする疾患です。感染症、化学療法、先天性骨髄異常、自己免疫疾患、一部の薬剤（薬剤性好中球減少症）など、さまざまな状況や疾患によって引き起こされます。好中球は、椎骨、肋骨、骨盤などの大きな骨に見られるスポンジ状の組織である骨髄で作られます。好中球減少症の治療には、体を攻撃する有害な真菌、酵母、細菌を破壊して感染と闘うのを助ける抗生物質、抗真菌薬、抗ウイルス薬が含まれます。これらの薬剤は感染の可能性を減らし、骨髄を刺激してより多くの白血球を産生させるのに役立ちます。

好中球減少症治療の市場動向：

好中球減少症や化学療法関連の副作用に対する意識の高まりは、市場成長を促進する主要要因の1つです。これに伴い、カプセルや錠剤の形態で入手可能で、投与経路が簡便な経口薬への需要が高まっていることも、市場の成長を後押ししています。さらに、主要企業は好中球減少症の予防措置、早期診断、効果的な治療に関する関連情報や知識の普及に積極的に取り組んでおり、これが市場成長を後押ししています。さらに、利用可能な治療選択肢に関する大衆の意識の高まりも、もう一つの成長促進要因として作用しています。これに加えて、メーカーは好中球減少症治療のための費用対効果の高い医薬品の採用注力しており、これが市場の成長を促進しています。さらに、患者の利便性を向上させ、アドヒアランスの改善につながる新しいドラッグデリバリー方法の利用が、市場成長にプラスの影響を与えています。このほか、発熱性好中球減少症治療の増加や、バイオシミラーの普及と製造のための新たな法律の施行が、市場に明るい展望をもたらしています。また、登録サイトなどのオンライン小売ポータルを通じて医薬品が簡単に入手できるため、手頃な価格帯で医薬品の注文や調達ができる利便性も市場を牽引しています。その他の要因としては、広範な研究開発（R&D）活動、革新的で効果的な医薬品の採用、がん罹患率の上昇、インフラの改善による医療施設への容易なアクセス、消費者の支出能力の増加、公衆衛生促進のための政府の様々なイニシアチブの実施などが挙げられ、市場の成長を促進すると予想されます。

本レポートで扱う主要質問

  • 世界の好中球減少症治療市場の規模は？
  • 2024～2032年にかけての世界の好中球減少症治療市場の予想成長率は？
  • 世界の好中球減少症治療市場を牽引する主要因は何か？
  • COVID-19が世界の好中球減少症治療市場に与えた影響は？
  • 治療法別の世界の好中球減少症治療市場の内訳は？
  • 世界の好中球減少症治療市場の流通チャネル別の区分は？
  • 世界の好中球減少症治療市場における主要地域は？
  • 世界の好中球減少症治療市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界の好中球減少症治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療別

  • コロニー刺激因子
  • 抗生物質
  • 抗真菌薬
  • 抗ウイルス剤

第7章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • BeyondSpring Inc.
    • Kyowa Hakko Kirin Co. Ltd.（Kirin Holdings Company Limited）
    • Pfizer Inc.
    • Sandoz Inc.（Novartis AG）
    • Spectrum Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
図表

List of Figures

  • Figure 1: Global: Neutropenia Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Neutropenia Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Neutropenia Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Neutropenia Treatment Market: Breakup by Treatment (in %), 2023
  • Figure 5: Global: Neutropenia Treatment Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Neutropenia Treatment Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Neutropenia Treatment (Colony-Stimulating Factors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Neutropenia Treatment (Colony-Stimulating Factors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Neutropenia Treatment (Antibiotics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Neutropenia Treatment (Antibiotics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Neutropenia Treatment (Antifungals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Neutropenia Treatment (Antifungals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Neutropenia Treatment (Antivirals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Neutropenia Treatment (Antivirals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Neutropenia Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Neutropenia Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Neutropenia Treatment (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Neutropenia Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Neutropenia Treatment (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Neutropenia Treatment (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: North America: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: North America: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: United States: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: United States: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Canada: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Canada: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Asia-Pacific: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Asia-Pacific: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: China: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: China: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Japan: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Japan: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: India: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: India: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: South Korea: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: South Korea: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Australia: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Australia: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Indonesia: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Indonesia: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Others: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Others: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Europe: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Europe: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Germany: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Germany: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: France: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: France: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: United Kingdom: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: United Kingdom: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Italy: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Italy: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Spain: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Spain: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Russia: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Russia: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Others: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Others: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Latin America: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Latin America: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Brazil: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Brazil: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Mexico: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Mexico: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Others: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Others: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Middle East and Africa: Neutropenia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Middle East and Africa: Neutropenia Treatment Market: Breakup by Country (in %), 2023
  • Figure 69: Middle East and Africa: Neutropenia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Global: Neutropenia Treatment Industry: Drivers, Restraints, and Opportunities
  • Figure 71: Global: Neutropenia Treatment Industry: Value Chain Analysis
  • Figure 72: Global: Neutropenia Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Neutropenia Treatment Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Neutropenia Treatment Market Forecast: Breakup by Treatment (in Million US$), 2024-2032
  • Table 3: Global: Neutropenia Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Neutropenia Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Neutropenia Treatment Market: Competitive Structure
  • Table 6: Global: Neutropenia Treatment Market: Key Players
目次
Product Code: SR112024A6852

The global neutropenia treatment market size reached US$ 15.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 23.8 Billion by 2032, exhibiting a growth rate (CAGR) of 4.9% during 2024-2032. The increasing adoption of cloud platforms, escalating sales of smartphones and extensive research and development (R&D) activities represent some of the key factors driving the market.

Neutropenia is a disease characterized by an abnormally low count of white blood cells (WBCs) that help the body fight infections. It is caused by various situations or diseases, including infections, chemotherapy, congenital bone marrow abnormalities, autoimmune disorders, and some medications (drug-induced neutropenia). Neutrophils are made in the bone marrow, which is the spongy tissue found in larger bones, such as the vertebrae, ribs, and pelvis. Neutropenia treatment includes antibiotics, antifungals, and antiviral medications that help fight against infection by destroying harmful fungi, yeast, and bacteria that attack the body. These medications assist in reducing the likelihood of infections and stimulate the bone marrow to produce more white blood cells.

Neutropenia Treatment Market Trends:

The rising awareness of neutropenia and chemotherapy-related side effects is one of the key factors driving the market growth. In line with this, the increasing demand for oral drugs that are available in capsule and tablet form and consist of convenient routes of administration is favoring the market growth. Moreover, key players are actively engaged in disseminating relevant information and knowledge regarding preventive measures, early diagnosis, and effective treatment of neutropenia, which, in turn, is propelling the market growth. Furthermore, the increasing awareness among the masses regarding the available treatment alternatives is acting as another growth-inducing factor. In addition to this, manufacturers are focusing on the introduction of cost-effective medicines for neutropenia treatment, which is facilitating the market growth. Additionally, the utilization of novel drug delivery methods that helps in improving patient convenience, which leads to improved patient adherence, is positively influencing the market growth. Besides this, the increase in febrile neutropenia medications and the implementation of new legislation to promote and manufacture biosimilars are creating a positive outlook for the market. The market is also driven by the easy availability of medications through online retail portals, such as registered websites, which provides convenience of ordering and procurement of medications at affordable price-points. Other factors, including extensive research and development (R&D) activities, the introduction of innovative and effective drugs, rising incidences of cancer, easy access to healthcare facilities owing to improved infrastructure, increasing expenditure capacities of consumers and the implementation of various government initiatives for promoting public health, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global neutropenia treatment market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on treatment and distribution channel.

Treatment Insights:

Colony-Stimulating Factors

Antibiotics

Antifungals

Antivirals

The report has provided a detailed breakup and analysis of the neutropenia treatment market based on the treatment. This includes colony-stimulating factors, antibiotics, antifungals and antivirals. According to the report, colony-stimulating factors represented the largest segment.

Distribution channel Insights:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

The report has provided a detailed breakup and analysis of the neutropenia treatment market based on the distribution channel. This includes hospital, retail, and online pharmacies. According to the report, hospital pharmacies represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for neutropenia treatment. Some of the factors driving the North America neutropenia treatment market included increasing demand for internet-enabled services by enterprises, extensive research and development (R&D) activities, and various technological advancements.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global neutropenia treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amgen Inc., BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd. (Kirin Holdings Company Limited), Pfizer Inc., Sandoz Inc. (Novartis AG), Spectrum Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global neutropenia treatment market?
  • 2. What is the expected growth rate of the global neutropenia treatment market during 2024-2032?
  • 3. What are the key factors driving the global neutropenia treatment market?
  • 4. What has been the impact of COVID-19 on the global neutropenia treatment market?
  • 5. What is the breakup of the global neutropenia treatment market based on the treatment?
  • 6. What is the breakup of the global neutropenia treatment market based on the distribution channel?
  • 7. What are the key regions in the global neutropenia treatment market?
  • 8. Who are the key players/companies in the global neutropenia treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neutropenia Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment

  • 6.1 Colony-Stimulating Factors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Antibiotics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Antifungals
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Antivirals
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 Drivers, Restraints, and Opportunities

  • 9.1 Overview
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Opportunities

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amgen Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 BeyondSpring Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 Kyowa Hakko Kirin Co. Ltd. (Kirin Holdings Company Limited)
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Pfizer Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Sandoz Inc. (Novartis AG)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 SWOT Analysis
    • 13.3.6 Spectrum Pharmaceuticals Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Teva Pharmaceutical Industries Ltd.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Viatris Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.